drugset
drugset / Trial / NCT06170489

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

NCT06170489 ↗

Phase 3 Recruiting 185 enrolled Shanghai Junshi Bioscience Co., Ltd.
RandomizedParallel-groupSingle-blindTreatment

Summary

The study is being conducted to compare JS004 plus Toripalimab with Investigator-Selected Chemotherapy in Patients with PD-(L)1 monoclonal antibody refractory Classic Hodgkin Lymphoma (cHL)

Timeline

Start
2023-12-28
Primary completion
2025-05-31
Completion
2027-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bendamustine Small molecule 90 mg/m2 Intravenous
Comparator Bendamustine Small molecule 120 mg/m2 Intravenous
Comparator Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Tifcemalimab Monoclonal antibody 200 mg Intravenous
Subject Toripalimab Monoclonal antibody 240 mg Intravenous

Indications

Hodgkins lymphoma